Nanomedicine in Europe: present and for the future
Date: 02-06-2010 - 02-06-2010
Location: Brussel
Description:
Ten of Europe’s foremost experts will initiate discussion from their various viewpoints on the present state of nanomedicine in Europe and on the key issues and requirements likely to determine its future.
The application of nanotechnology in medicine and healthcare is not just a theoretical possibility any longer because more than forty products are already in use. However, the field is still relatively new which means that Europe is at an ideal moment to consider the possible impacts and consequences of nanomedicine as well as the actions required as a result. To take the right actions in a timely manner it is crucial to have reliable data about the main areas of nanomedicine, the infrastructures required for rapid translation of R&D results into clinical applications and its societal, economic, ethical and regulatory environments. The meeting will address all these topics based on information and advice gathered from more than 100 leading experts from academia, industry, regulatory agencies and, patient organisations, ethics and public communication throughout Europe during the Nanomed Round Table, EuroNanoBio and Nanomedicine European Technology Platform initiatives.
The event will provide clear evidence that not taking action responsibly now would be wasting opportunity. By doing too little or too late or nothing, Europe would significantly risk hindering or even blocking the development of these innovations in Europe to the detriment of European research and development, its healthcare industries, and, most importantly, patients which is all of us. It’s never too early to act until it’s too late.
Programme
14.00 Press Conference: Chairmen and all speakers
14.30 Welcome and introduction: Chairmen: Mr Correia de Campos MEP, STOA Vice-Chairman & Prof Sir John
Beringer, former Pro Vice-Chancellor, University of Bristol, UK (Nanomed Round Table chairman)
14.40 Nanomedicine in the EC’s Action Plans for Nanotechnology: Christos Tokamanis, Head of Unit, Operational Unit Nanosciences and Nanotechnologies, European Commission
15.00 Nanomedicine to 2020: Patrick Boisseau, CEA, (ETP Nanomedicine, Coordinator Nano2Life Network of Excellence and EuroNanoBio)
15.20 Changing academia/industry relations for nanomedicine: Mike Eaton, formerly Head of Biological Chemistry UCB and Senior Principal Scientist at UCB Pharma (ETP Nanomedicine)
15.40 The view from a small nanomed company – MagForce Nanotechnologies AG: Dr. Andreas Jordan, founder and Chief Scientific Officer (Nanomed Round Table)
16.00 Nanomedicine in the broader field of nanotechnology’s present and future: Dr Steffi Friedrichs, Director of the Nanotechnology Industries Association (NIA)
16.20 Patients’ views and needs: Alastair Kent, President, European Genetic Alliances' Network (EGAN); Director, Genetic Interest Group (GIG), London; Chairman. European Platform for Patients’ Organisations, Science and Industry (EPPOSI) (Nanomed Round Table)
16.40 The regulatory framework: Prof Julian Kinderlerer, Delft University of Technology and University of Cape Town, member of the EC’s European Group on Ethics (Nanomed Round Table and Nanobio-RAISE)
17.00 Safety aspects and risk assessment issues: Robert Geertsma, Netherlands National Institute for Public Health and the Environment (RIVM) (Nanomed Round Table)
17.20 Ethical and societal considerations: Prof Alfred Nordmann, Technische Universität Darmstadt and University of
South Carolina (Nanomed Round Table, DEEPEN, NanoCap, ObservatoryNano, EthicSchool)
17.40 Engaging the public: Prof Wolfgang Heckl, General Director, Deutsches Museum, Munich (Nanomed Round Table, NANOTOTOUCH)
18.00 Plenary panel discussion: Chairmen and all speakers
18.30 Close and cocktail reception
More information: http://www.nanomedroundtable.org
Email address: info@eu-patient.eu